Anteris Technologies Global (NASDAQ:AVR) vs. NeurAxis (NASDAQ:NRXS) Critical Analysis

Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Risk & Volatility

Anteris Technologies Global has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Profitability

This table compares Anteris Technologies Global and NeurAxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anteris Technologies Global -4,637.48% -57.15% -50.73%
NeurAxis -492.76% N/A -641.25%

Institutional & Insider Ownership

11.8% of NeurAxis shares are owned by institutional investors. 2.5% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Anteris Technologies Global and NeurAxis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anteris Technologies Global 1 1 3 0 2.40
NeurAxis 0 1 1 0 2.50

Anteris Technologies Global presently has a consensus price target of $13.75, indicating a potential upside of 153.69%. NeurAxis has a consensus price target of $13.00, indicating a potential upside of 139.85%. Given Anteris Technologies Global’s higher possible upside, research analysts clearly believe Anteris Technologies Global is more favorable than NeurAxis.

Valuation and Earnings

This table compares Anteris Technologies Global and NeurAxis”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anteris Technologies Global $1.91 million 276.65 -$94.14 million ($1.61) -3.37
NeurAxis $6.53 million 8.84 -$14.63 million ($1.06) -5.11

NeurAxis has higher revenue and earnings than Anteris Technologies Global. NeurAxis is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Summary

NeurAxis beats Anteris Technologies Global on 9 of the 14 factors compared between the two stocks.

About Anteris Technologies Global

(Get Free Report)

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.